Stay ahead of the curve with the latest developments in the biopharma industry through BioPharma Dive’s informative newsletter, conveniently delivered to your inbox. Recent news highlights include the FDA’s cancellation of an adcomm meeting on a Biohaven drug and Catalent’s decision to lay off 350 employees due to a shift in demand at their gene therapy facility in Baltimore, now under Novo Holdings’ ownership. Meanwhile, Stealth Biotherapeutics’ revised approval submission for a rare disease drug has been accepted by the FDA, with a decision expected by September 26.
Jazz Pharmaceuticals recently acquired rights to an experimental epilepsy medicine in a deal potentially exceeding $1 billion in value. The drug, SAN2355, shows promise in activating specific potassium ion channels and is poised to bolster Jazz’s neuroscience portfolio. On the other hand, Celldex Therapeutics’ Phase 2 trial results for barzolvolimab in treating eosinophilic esophagitis did not meet expectations, although the drug demonstrated favorable safety profiles, hinting at its potential in ongoing trials for urticaria.
In the realm of cancer therapeutics, the emergence of bispecific drugs targeting PD-1 and VEGF presents a promising avenue to enhance existing immunotherapy treatments like Keytruda. Recent study results have underscored the potential of these drugs to revolutionize cancer treatment, sparking heightened research interest in the field. Additionally, a lineup of upcoming clinical trials in obesity, lung cancer, and AATD promises to deliver pivotal insights that could significantly impact the biotechnology sector in the coming years.
Key Takeaways:
– Stay informed on industry trends and breakthroughs in clinical trials, gene therapy, and immunotherapy through BioPharma Dive’s newsletter.
– Significant developments include FDA actions on Biohaven and Stealth Biotherapeutics, Jazz Pharmaceuticals’ strategic acquisition, and Celldex Therapeutics’ trial outcomes.
– The evolving landscape of cancer therapeutics, particularly bispecific drugs, holds promise for advancing immunotherapy treatments.
– Anticipated clinical trial results in various disease areas offer valuable opportunities for industry growth and innovation.
Tags: clinical trials, gene therapy, biopharma, immunotherapy, biotech
Read more on biopharmadive.com